	US 12,258,390 B2
	Methods and agents for the treatment of ocular disease
Brian W. Ziegelaar, Brisbane (AU); and Garry L. Redlich, Brisbane (AU)
Assigned to Line 6 Biotechnology, Inc., Seattle, WA (US)
Filed by Line 6 Biotechnology, Inc., Seattle, WA (US)
Filed on Jan. 27, 2023, as Appl. No. 18/160,355.
Application 18/160,355 is a continuation of application No. 17/678,861, filed on Feb. 23, 2022, granted, now 11,618,782.
Application 17/678,861 is a continuation of application No. PCT/AU2021/051173, filed on Oct. 7, 2021.
Claims priority of application No. 2020903624 (AU), filed on Oct. 7, 2020.
Prior Publication US 2024/0002489 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/22 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)

CPC C07K 16/22 (2013.01) [C07K 16/468 (2013.01); C07K 16/28 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01)]

18 Claims

1. A method for reducing ocular fibrosis in a subject with wet age-related macular degeneration (AMD) and ocular fibrosis, comprising administering to the eye of the subject an amount of a CD14 antagonist antibody, or antigen binding fragment thereof, effective to reduce ocular fibrosis in the subject, wherein the CD14 antagonist antibody, or antigen binding fragment thereof, is either administered alone or in combination with an anti-VEGF agent.